AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19404392 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily acyclovir for genital herpes (HSV-2) suppression
Number of subjects: 3408
Study 19404392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3408
Study 17525360 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial sensory re-training exercises
Number of subjects: 100
Study 17525360 — intervention group
Group type: COMPARATOR
Intervention: Standard opening exercises (Control)
Number of subjects: 100
Study 15383110 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (diamorphine 1.2 mg loading dose intravenously)
Number of subjects: 0
Study 15383110 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular diamorphine (as per hospital protocol)
Number of subjects: 0
Study 11149996 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass pollen immunotherapy (n = 22)
Number of subjects: 44
Study 11149996 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 44
Study 10432871 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand B (best manufacture)
Number of subjects: 0
Study 10432871 — intervention group
Group type: EXPERIMENTAL
Intervention: Gloves worn longer than 2 hours
Number of subjects: 0
Study 10432871 — intervention group
Group type: COMPARATOR
Intervention: Surgeons
Number of subjects: 0
Study 10432871 — intervention group
Group type: COMPARATOR
Intervention: Others
Number of subjects: 0
Study 10432871 — intervention group
Group type: COMPARATOR
Intervention: Subjects with allergy history
Number of subjects: 0
Study 10432871 — intervention group
Group type: COMPARATOR
Intervention: Subjects without allergy history
Number of subjects: 0
Study 7584951 — intervention group
Group type: EXPERIMENTAL
Intervention: Cationic liposome complexed with CFTR cDNA
Number of subjects: 15
Study 7584951 — intervention group
Group type: COMPARATOR
Intervention: Liposome only (control)
Number of subjects: 15
Study 2407813 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant single-agent chemotherapy with doxorubicin
Number of subjects: 148
Study 2407813 — intervention group
Group type: EXPERIMENTAL
Intervention: None or one risk factor
Number of subjects: 148
Study 2407813 — intervention group
Group type: EXPERIMENTAL
Intervention: Two risk factors
Number of subjects: 148
Study 2407813 — intervention group
Group type: EXPERIMENTAL
Intervention: Three risk factors
Number of subjects: 148
Study 2407813 — intervention group
Group type: EXPERIMENTAL
Intervention: Four and five risk factors
Number of subjects: 148
Study 2407813 — intervention group
Group type: EXPERIMENTAL
Intervention: Three factors or less
Number of subjects: 148
Study 7001863 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretics (bendroflumethiazide, chlorthalidone, hydrochlorothiazide)
Number of subjects: 18
Study 7001863 — intervention group
Group type: COMPARATOR
Intervention: Loop diuretics (bumetanide, furosemide, triamterene)
Number of subjects: 18
Study 31027477 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer coaching with iDecide (interactive web-based tool)
Number of subjects: 290
Study 31027477 — intervention group
Group type: COMPARATOR
Intervention: Peer coaching with nontailored educational materials
Number of subjects: 290
Study 28905377 — intervention group
Group type: EXPERIMENTAL
Intervention: Group prenatal care (PNC)
Number of subjects: 193
Study 28905377 — intervention group
Group type: COMPARATOR
Intervention: Individual prenatal care (PNC)
Number of subjects: 193
Study 25791173 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (Tisseel) applied to the uterine cervix (2 ml)
Number of subjects: 40
Study 25791173 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrin sealant)
Number of subjects: 40
Study 23403384 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 207
Study 23403384 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent
Number of subjects: 207
Study 20801938 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat (2.5 mg, 3 times daily for 10 days)
Number of subjects: 30
Study 20801938 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (25 mg single oral dose)
Number of subjects: 30
Study 20801938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19525733 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Activities Questionnaire (VAQ)
Number of subjects: 426
Study 19525733 — intervention group
Group type: EXPERIMENTAL
Intervention: National Eye Institute-Visual Function Questionnaire (NEI-VFQ)
Number of subjects: 426
Study 19525733 — intervention group
Group type: COMPARATOR
Intervention: Visual Activities Questionnaire (VAQ) and National Eye Institute-Visual Function Questionnaire (NEI-VFQ)
Number of subjects: 426
Study 19525733 — intervention group
Group type: COMPARATOR
Intervention: Clinical measures of visual function
Number of subjects: 426
Study 19525733 — intervention group
Group type: COMPARATOR
Intervention: Visual field (VF) loss
Number of subjects: 426
Study 17138821 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intensity FAB/LMB therapy
Number of subjects: 190
Study 17138821 — intervention group
Group type: COMPARATOR
Intervention: Reduced intensity therapy (reduced cytarabine plus etoposide and deletion of 3 maintenance courses M2, M3, M4)
Number of subjects: 190
Study 17138821 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined BM/CNS disease at diagnosis or poor response to COP reduction therapy
Number of subjects: 190
Study 14500060 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led sex education
Number of subjects: 29
Study 14500060 — intervention group
Group type: COMPARATOR
Intervention: Teacher-led sex education (Control)
Number of subjects: 29
Study 10872909 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (1%) in vaginal hydrophilic gel
Number of subjects: 60
Study 10872909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8843042 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise (three 40‐min sessions of brisk walking a week for 6 months)
Number of subjects: 177
Study 8843042 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 177
Study 1616253 — intervention group
Group type: EXPERIMENTAL
Intervention: Actapulgite
Number of subjects: 113
Study 1616253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 6437430 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesna (2‐mercaptoethane sulphonate sodium)
Number of subjects: 61
Study 6437430 — intervention group
Group type: COMPARATOR
Intervention: Forced diuresis
Number of subjects: 61
Study 3743860 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine alone
Number of subjects: 44
Study 3743860 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine combined with pindolol
Number of subjects: 44
Study 3743860 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with hydralazine and pindolol
Number of subjects: 44
Study 3743860 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 44
Study 31924631 — intervention group
Group type: COMPARATOR
Intervention: Intervention (not specified)
Number of subjects: 226
Study 31924631 — intervention group
Group type: COMPARATOR
Intervention: Cost-effectiveness analysis
Number of subjects: 226
Study 29198305 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mask (NM)
Number of subjects: 48
Study 29198305 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mask plus chinstrap (NM-CS)
Number of subjects: 48
Study 29198305 — intervention group
Group type: EXPERIMENTAL
Intervention: Oronasal mask (ONM)
Number of subjects: 48
Study 27955663 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFA) 3g daily for 24 weeks
Number of subjects: 145
Study 27955663 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 145
Study 25048468 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafix (human viable wound matrix)
Number of subjects: 97
Study 25048468 — intervention group
Group type: COMPARATOR
Intervention: Standard wound care (control)
Number of subjects: 97
Study 22700161 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline plus methylphenidate
Number of subjects: 43
Study 22700161 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methylphenidate
Number of subjects: 43
Study 21132128 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating (light standard meal)
Number of subjects: 6
Study 21132128 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged supine position
Number of subjects: 6
Study 21132128 — intervention group
Group type: COMPARATOR
Intervention: Fasting (control condition)
Number of subjects: 6
Study 18640468 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide 2% BID added to timolol maleate 0.5% BID
Number of subjects: 40
Study 18640468 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate 0.5% BID (control)
Number of subjects: 40
Study 18640468 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide and timolol
Number of subjects: 40
Study 15792398 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen sodium dihydrate (2 x 200 mg t.i.d.)
Number of subjects: 38
Study 15792398 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen sodium dihydrate
Number of subjects: 38
Study 15792398 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen arginate (2 x 200 mg t.i.d.)
Number of subjects: 38
Study 12787013 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp cooling via gel cool caps
Number of subjects: 40
Study 12787013 — intervention group
Group type: COMPARATOR
Intervention: No specific preventative intervention (Control)
Number of subjects: 40
Study 10984365 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone (100 microg twice daily) for 7 days
Number of subjects: 210
Study 10984365 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 210
Study 10984365 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone (100 microg twice daily) for 7 days in children with rhinovirus infection
Number of subjects: 210
Study 10984365 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days in children with rhinovirus infection
Number of subjects: 210
Study 8771597 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (Neurontin)
Number of subjects: 694
Study 8771597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 694
Study 1730841 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Challenge (EC)
Number of subjects: 11
Study 1730841 — intervention group
Group type: COMPARATOR
Intervention: Control Studies
Number of subjects: 11
Study 6486559 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of slow-release theophylline (TheoDur) twice a day
Number of subjects: 10
Study 30270639 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (ACT) 1 g
Number of subjects: 16
Study 29202655 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 80
Study 29202655 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 80
Study 27404031 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (1 mg/d, n=22)
Number of subjects: 44
Study 27404031 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=22)
Number of subjects: 44
Study 24874565 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g oat bran
Number of subjects: 42
Study 24874565 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g barley bran
Number of subjects: 42
Study 24874565 — intervention group
Group type: COMPARATOR
Intervention: low fiber condition
Number of subjects: 42
Study 24874565 — intervention group
Group type: EXPERIMENTAL
Intervention: ad libitum pizza lunch
Number of subjects: 42
Study 22883013 — intervention group
Group type: EXPERIMENTAL
Intervention: VCu IUD
Number of subjects: 400
Study 22883013 — intervention group
Group type: COMPARATOR
Intervention: TCu380A IUD
Number of subjects: 400
Study 21095280 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg/d)
Number of subjects: 107
Study 21095280 — intervention group
Group type: COMPARATOR
Intervention: Eplerenone (50 mg/d)
Number of subjects: 107
Study 18211446 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (anaesthetic concentration)
Number of subjects: 0
Study 18211446 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine (anaesthetic concentration)
Number of subjects: 0
Study 18211446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (anaesthetic concentration)
Number of subjects: 0
Study 18211446 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (analgesic concentration)
Number of subjects: 0
Study 18211446 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine (analgesic concentration)
Number of subjects: 0
Study 18211446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (analgesic concentration)
Number of subjects: 0
Study 16403053 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 192
Study 16403053 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 192
Study 14640055 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors
Number of subjects: 0
Study 14640055 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 10781471 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam plus fentanyl (0.03 mg/kg plus 2 microg/kg)
Number of subjects: 180
Study 10781471 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (2 microg/kg)
Number of subjects: 180
Study 10781471 — intervention group
Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 180
Study 10781471 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedicated patients older than 60 yr
Number of subjects: 180
Study 8787937 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (0.4 U.kg‐1.week‐1) for 6 months
Number of subjects: 16
Study 8787937 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (0.25 U.kg‐1.week‐1) for 24 months
Number of subjects: 16
Study 1621247 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg d-indobufen
Number of subjects: 10
Study 1621247 — intervention group
Group type: COMPARATOR
Intervention: 200 mg dl-indobufen
Number of subjects: 10
Study 3883734 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (2 mg oral dose)
Number of subjects: 6
Study 3883734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30383438 — intervention group
Group type: EXPERIMENTAL
Intervention: HF educational board game conducted in Thai language
Number of subjects: 76
Study 30383438 — intervention group
Group type: COMPARATOR
Intervention: Usual care including standard education
Number of subjects: 76
Study 30404622 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC) in the active pill phase (20th to 21st day of OC cycle)
Number of subjects: 51
Study 30404622 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC) in the inactive pill phase (2nd to 4th day of OC cycle)
Number of subjects: 51
Study 30404622 — intervention group
Group type: COMPARATOR
Intervention: Naturally cycling women (NCW) in the early follicular phase (4th - 5th days)
Number of subjects: 51
Study 30404622 — intervention group
Group type: COMPARATOR
Intervention: Naturally cycling women (NCW) in the mid-luteal phase (20th-21st days)
Number of subjects: 51
Study 27287206 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN (180 μg subcutaneously 1×/week; 24 months)
Number of subjects: 909
Study 27287206 — intervention group
Group type: COMPARATOR
Intervention: IFN α‐2a (3MIU subcutaneously 3×/week; 24 months)
Number of subjects: 909
Study 27287206 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN
Number of subjects: 909
Study 27287206 — intervention group
Group type: COMPARATOR
Intervention: IFN
Number of subjects: 909
Study 27287206 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN and IFN
Number of subjects: 909
Study 24135621 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa treatment (balneotherapy) for 3 weeks, consisting of four sessions per day for 6 days a week.
Number of subjects: 425
Study 24135621 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa treatment (balneotherapy) for 3 weeks.
Number of subjects: 425
Study 24135621 — intervention group
Group type: COMPARATOR
Intervention: Control group received spa treatment after 1 year.
Number of subjects: 425
Study 23451463 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoplasty
Number of subjects: 64
Study 23451463 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 64
Study 20087785 — intervention group
Group type: EXPERIMENTAL
Intervention: SLN positive patients with micrometastases (deposits < or =2 mm but >0.2 mm)
Number of subjects: 381
Study 20087785 — intervention group
Group type: EXPERIMENTAL
Intervention: SLN positive patients with macrometastases (deposits >2 mm)
Number of subjects: 381
Study 20087785 — intervention group
Group type: EXPERIMENTAL
Intervention: SLN positive patients with submicrometastases (deposits < or =0.2 mm)
Number of subjects: 381
Study 20087785 — intervention group
Group type: COMPARATOR
Intervention: Negative SLN patients
Number of subjects: 381
Study 18385443 — intervention group
Group type: EXPERIMENTAL
Intervention: HerpeSelect assay
Number of subjects: 434
Study 18385443 — intervention group
Group type: EXPERIMENTAL
Intervention: Kalon assay
Number of subjects: 434
Study 15823104 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular access ports (22 cases)
Number of subjects: 60
Study 15823104 — intervention group
Group type: COMPARATOR
Intervention: Conventional vascular access (38 cases)
Number of subjects: 60
Study 12479668 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral loading dose of valproate (20 mg/kg/day)
Number of subjects: 11
Study 12479668 — intervention group
Group type: COMPARATOR
Intervention: Slower titration dose of valproate (10 mg/kg/day)
Number of subjects: 11
Study 10512897 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trials of interventions for acute stroke
Number of subjects: 0
Study 10512897 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical industry involvement
Number of subjects: 0
Study 10512897 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially supported trials
Number of subjects: 0
Study 8534459 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxacurium
Number of subjects: 60
Study 2333839 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil-based diet
Number of subjects: 20
Study 2333839 — intervention group
Group type: EXPERIMENTAL
Intervention: High-oleic acid sunflower oil-based diet
Number of subjects: 20
Study 2333839 — intervention group
Group type: COMPARATOR
Intervention: Butter-based diet
Number of subjects: 20
Study 389814 — intervention group
Group type: EXPERIMENTAL
Intervention: co‐trimoxazole
Number of subjects: 105
Study 389814 — intervention group
Group type: EXPERIMENTAL
Intervention: co‐trimazine
Number of subjects: 105
Study 389814 — intervention group
Group type: COMPARATOR
Intervention: sulphalene
Number of subjects: 105
Study 31149842 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation (TSD) for 24 hours
Number of subjects: 27
Study 31149842 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep
Number of subjects: 27
Study 28435501 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS)
Number of subjects: 613
Study 28435501 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CDS)
Number of subjects: 613
Study 24337500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 119
Study 24337500 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 119
Study 23457080 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin plus trimethoprim-sulfamethoxazole
Number of subjects: 153
Study 23457080 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin alone (placebo group)
Number of subjects: 153
Study 21353372 — intervention group
Group type: EXPERIMENTAL
Intervention: MVI 50 (misoprostol 50 mcg)
Number of subjects: 1308
Study 21353372 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone
Number of subjects: 1308
Study 18582848 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (maximum dose 20 mg/day)
Number of subjects: 20
Study 18582848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16861151 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic analgesic nitrous oxide (PAN)
Number of subjects: 101
Study 16861151 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100% oxygen)
Number of subjects: 101
Study 14640255 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid lowering treatment
Number of subjects: 0
Study 10828728 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ropinirole
Number of subjects: 12
Study 10828728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9181161 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral position
Number of subjects: 56
Study 9181161 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 56
Study 9181161 — intervention group
Group type: EXPERIMENTAL
Intervention: Kneeling position
Number of subjects: 56
Study 9181161 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 56
Study 8024107 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming group (unprotected water exposure)
Number of subjects: 212
Study 8024107 — intervention group
Group type: COMPARATOR
Intervention: Nonswimming group (no unprotected water exposure)
Number of subjects: 212
Study 2684622 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 IU/kg/week r-hGH
Number of subjects: 94
Study 2684622 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 IU/kg/week r-hGH
Number of subjects: 94
Study 2684622 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 94
Study 2684622 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 94
Study 1035402 — intervention group
Group type: EXPERIMENTAL
Intervention: Halcinonide-neomycin-nystatin (HNN)
Number of subjects: 64
Study 1035402 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone (HC)
Number of subjects: 64
Study 1035402 — intervention group
Group type: COMPARATOR
Intervention: Iodochlorhydroxyquin-hydrocortisone (I-HC)
Number of subjects: 64